A股異動 | 科倫藥業(002422.SZ)直線拉昇漲超3% 創新藥物KL-A289注射液獲臨牀試驗通知書
格隆匯8月4日丨科倫藥業(002422.SZ)午後直線拉昇,現報23.58元,漲3.15%,暫成交4.6億元,最新總市值339億元。科倫藥業今日午間公佈,公司於近日獲悉,公司控股子公司四川科倫博泰生物醫藥股份有限公司與安源醫藥科技(上海)有限公司共同開發的創新腫瘤免疫藥物KL-A289注射液獲得國家藥品監督管理局臨牀試驗通知書。截至目前,公司在KL-A289注射液項目上已投入研發費用約2252萬元人民幣。公司將按照國家藥品監督管理局簽發的臨牀試驗通知書的要求,組織實施KL-A289注射液的臨牀試驗。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.